Aurobindo Pharma’s step-down subsidiary -- Eugia SEZ has received Establishment Inspection Report for Telangana facility, classifying the facility as Voluntary Action Indicated (VAI). The U.S. Food and Drug Administration (USFDA) had conducted an inspection at the injectable facility of Eugia SEZ, situated at Polepally Village, Jadcherla Mandal, Mahaboobnagar District, Telangana, from February 19, 2024 to February 29, 2024.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
